Recent data questions high dose usage in the early therapy phases for rheumatoid arthritis (RA) with oral methotrexate (MTX).
Awareness of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) began to rise in 2011 when the FDA released a report on some of these cases. Since then, several studies confirmed this interlink with a recent Dutch population-based, case-control study adding crucial insights into it.
A study from the University of Illinois at Chicago has found that women are at the highest risk for heart failure within the six weeks after delivery, known as the postpartum period.
Scientists have proposed that once individuals at risk of developing Alzheimer’s have been identified, a low-dose ibuprofen prophylaxis can be started to stop Alzheimer’s in its tracks.
Based on the available scientific knowledge and pre-clinical evidence, the University of Massachusetts Medical School has initiated multicenter, phase I clinical trial to investigate an HIV vaccine that might prevent HIV infection.
Scientists succeeded in detecting Parkinson's disease through a minimally invasive skin biopsy - years before the patient becomes noticeably ill.
Percutaneous Coronary Interventions (PCI) play a major role in cardiology, as they are the gold standard for the treatment of narrowed (stenosed) coronary vessels. However, the highly acclaimed stents are the target of new criticism.
The drug anakinra has been found to reduce harmful inflammation in the early stages of stroke, according to fresh research from Manchester University and the Salford Royal NHS Foundation.
Researchers have discovered a new mechanism by which live vaccines induce immunity. Molecules produced exclusively by live microorganisms are recognized by specialized receptors of the immune system, subsequently triggering a protective immune response.
Two recent studies suggest that NOACs promise better prophylaxis when compared to heparin standard use. On the other hand, the risk of bleeding is higher among NOACs. At a state-of-the-art symposium at GTH in Vienna, Prof. Dr. Anne Angelillo-Scherrer, University Clinic of Hematology and Central Hematology Laboratory Bern, presented which patients might be eligible for NOACs.